Repositive is on a mission to accelerate cancer drug development by improving translational success from preclinical research to clinical trials.
We provide unique, tailored cancer model search services to researchers working in the preclinical oncology space. Our work helps to connect biopharma with contract research organisations (CRO) from around the world to optimise opportunities for drug development success.
We are working to make the CRO landscape more accessible by levelling the playing field between large and small CROs and introducing new and unique technologies to our biopharma customers. Our model inventory includes a wide variety of model types, including patient-derived xenografts (PDX), cell-line derived xenografts (CDX), cell lines, syngeneic mouse models and organoids. This enables us to present our customers with a complete spectrum of preclinical cancer model options.